Back to search

Article

CDK4/6 Inhibition Uncovers Subtype-Specific Vulnerabilities and Immune-Related Responses in Esophageal Squamous Cell Carcinoma

2025-09-16

Abstract excerpt

Esophageal squamous cell carcinoma (eSCC) is a highly aggressive malignancy with poor prognosis and limited therapeutic options. Although immune checkpoint inhibitors such as nivolumab, have shown clinical benefit, particularly in patients with high PD-L1 expression, this subgroup represents only a small fraction of eSCC cases. CDK4/6 inhibitors such as palbociclib have only been tested as second-line agents in eS...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
6d14adc4-09ca-561a-a10c-cc504580939c
DOI
10.1101/2025.09.12.673056
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
CDK4/6 Inhibition Uncovers Subtype-Specific Vulnerabilities and Immune-Related Responses in Esophageal Squamous Cell CarcinomaDOI 10.1101/2025.09.12.673056
Clinical prognostication and immunotherapy response prediction in esophageal squamous cell carcinoma using the DNA damage repair‐associated signatureSemantic proximity
Exploratory Biomarker Analysis of Abemaciclib in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma With Dysregulated CDK4/6 Pathway.Semantic proximity
Dual CDK and MEK Inhibition potentiates CD8+ T cell-mediated antitumor immunity by inducing pyroptotic cell death in high-mutational head and neck cancer.Semantic proximity
New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune CheckpointsSemantic proximity
Comprehensive Single-Cell Transcriptomic Profiling Identifies Molecular Subtypes and Prognostic Biomarkers in Esophageal Squamous Cell Carcinoma: Implications for Targeted TherapySemantic proximity
CEP72 Promotes Malignant Progression and Shapes the Tumor Immune Microenvironment in Hepatocellular Carcinoma: Integrated Multi-cohort Bioinformatics and In Vitro ValidationSemantic proximity
Repurposing proteasome inhibitors in the treatment of esophageal squamous cell cancerSemantic proximity
Deregulated Immune Pathway Associated with Palbociclib Resistance in Preclinical Breast Cancer Models: Integrative Genomics and Transcriptomics.Semantic proximity
Enhancer demethylation-regulated gene score identified molecular subtypes, inspiring immunotherapy or CDK4/6 inhibitor therapy in oesophageal squamous cell carcinomaSemantic proximity
The Immune Microenvironment in Penile Squamous Cell Carcinoma: Distinctions Between HPV-Driven and HPV-Independent PathwaysSemantic proximity
Clinical Outcome-Related Cancer Pathways and Mutational Signatures in Patients With Unresectable Esophageal Squamous Cell Carcinoma Treated With Chemoradiotherapy.Semantic proximity
Transcriptomics based multi-dimensional characterization and drug screen in esophageal squamous cell carcinomaSemantic proximity
Select a neighboring publication to make it the new centre.